It can improve clinical symptom such as difficulty in breathing in patients with IPF, improve patients' life quality, pulmonary function, and pulmonary diffusion function [35, 36], inhibit collagen deposition of rat lung tissue, reduce the matrix metalloproteinase-1 (MMP-1) expression of matrix metalloproteinase-2 (MMP-2), restrain collagen-I (Col I) and collagen-III (Col-III), and reduce the accumulation of extracellular matrix [37–40]. Here, MMP1 is linked to idiopathic interstitial pneumonia.